Skip to Content

PACE Large Co Value Equity A PCPAX

Medalist Rating as of | See UBS Investment Hub
  • NAV / 1-Day Return 20.29  /  −1.31 %
  • Total Assets 798.2 Mil
  • Adj. Expense Ratio
    1.130%
  • Expense Ratio 1.130%
  • Distribution Fee Level Above Average
  • Share Class Type Front Load
  • Category Large Value
  • Investment Style Large Value
  • Min. Initial Investment 1,000
  • Status Open
  • TTM Yield 1.60%
  • Turnover 42%

USD | NAV as of Apr 12, 2024 | 1-Day Return as of Apr 12, 2024, 10:14 PM GMT+0

Morningstar’s Analysis PCPAX

Will PCPAX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

PACE Large Co Value Equity A's Average Process Pillar and People Pillar ratings result in a Morningstar Medalist Rating of Neutral.

null Morningstar Manager Research

Morningstar Manager Research

Summary

Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the second-costliest quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings PCPAX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 34.6
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Merck & Co Inc

4.22 21.1 Mil
Healthcare

JPMorgan Chase & Co

3.94 19.7 Mil
Financial Services

UnitedHealth Group Inc

3.57 17.8 Mil
Healthcare

Unilever PLC ADR

3.49 17.4 Mil
Consumer Defensive

Rio Tinto PLC ADR

3.36 16.8 Mil
Basic Materials

Gilead Sciences Inc

3.31 16.5 Mil
Healthcare

Gaming and Leisure Properties Inc

3.24 16.2 Mil
Real Estate

Pfizer Inc

3.20 16.0 Mil
Healthcare

General Dynamics Corp

3.20 16.0 Mil
Industrials

Philip Morris International Inc

3.08 15.4 Mil
Consumer Defensive